Company Description
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States.
Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis.
The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.
In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma.
Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies.
The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017.
Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Steven Kelly |
Contact Details
Address: 3675 Market Street, Suite 401 Philadelphia, Pennsylvania 19104 United States | |
| Phone | 267 491 6422 |
| Website | carismatx.com |
Stock Details
| Ticker Symbol | CARM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001485003 |
| CUSIP Number | 14216R101 |
| ISIN Number | US14216R1014 |
| Employer ID | 26-2025616 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven Kelly | President, Chief Executive Officer and Director |
| Michael Klichinsky Ph.D., Pharm.D., PharmD | Co-Founder and Chief Scientific Officer |
| Dr. Saar Gill M.D., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Natalie McAndrew | Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | 425 | Filing |
| Aug 8, 2025 | 8-K | Current Report |
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Jul 31, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 21, 2025 | S-4 | Filing |
| Jul 15, 2025 | 425 | Filing |
| Jul 15, 2025 | 8-K | Current Report |
| Jul 7, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 27, 2025 | PRE 14A | Other preliminary proxy statements |
| Jun 25, 2025 | 425 | Filing |